P PSMA ALLO1
Alternative Names: P-PSMA-ALLO1Latest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Poseida Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for preclinical development in Prostate-cancer in USA (Parenteral)
- 04 Jan 2024 Poseida Therapeutics anticipates an IND filing for P PSMA ALLO1 in Prostate cancer in 2024
- 12 Oct 2020 Preclinical trials in Prostate cancer in USA (Parenteral), prior to October 2020 (Poseida Therapeutics pipeline, October 2020)